Multicenter pilot study of 5-fluorouracil, folinic acid, interferon alpha-2b and degradable starch microspheres via hepatic arterial infusion in patients with nonresectable colorectal liver metastases

Anticancer Research

Volumn 24, Issue 5 B, 2004, Pages 3275-3282

  Pohlen, U ^a   Mansmann, U ^b   Berger, G ^a   Germer, C T ^a   Gallkowski, U ^c   Boese Landgraf, J ^d   Buhr, H J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d Dept of Surgery Klinikum Chemnitz ^*  (Germany)

Author keywords

5 fluorouracil; Colorectal liver metastases; Hepatic arterial infusion; Interferon; Starch microspheres

Indexed keywords

ALPHA2B INTERFERON; ALTEPLASE; DOLOREDUCT; FLUOROURACIL; FOLINIC ACID; METOCLOPRAMIDE; PARACETAMOL; PETHIDINE; RECOMBINANT ALPHA2B INTERFERON; STARCH MICROSPHERE;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; FEMALE; HAND FOOT SYNDROME; HUMAN; LEUKOPENIA; LIVER CIRCULATION; LIVER METASTASIS; LIVER TUMOR; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PRIORITY JOURNAL; SHIVERING; VOMITING;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CATHETERS, INDWELLING; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; INTERFERON ALFA-2B; LEUCOVORIN; LIVER NEOPLASMS; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; STARCH;

EID: 6344280554     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Parker SL, Tong T, Bolden S et al: Cancer statistics, 1997. CA Cancer J Clin 47: 5-27, 1997.
2. Silverberg E, Boring CS and Squires TS: Cancer statistics, 1990. CA Cancer J Clin 40: 9-26, 1990.
3. Black RJ, Bray F, Ferlay J et al: Cancer incidence and mortality in the European Union: Cancer registry data and estimates of national incidence for 1990. Eur J Cancer 33: 1075-107, 1997.
4. Taylor I, Mullee MA and Campbell MJ: Prognostic index for the development of liver metastases in patients with colorectal cancer. Br J Surg 77: 499-501, 1990.
5. Ishizuka D, Shirai Y, Sakai Y and Hatakeyama K: Colorectal carcinoma liver metastases: clinical significance of preoperative measurement of serum carcinoembryonic antigen and carbohydrate antigen 19-9 levels. Int J Colorectal Dis 16: 32-37, 2001.
6. Weiss L, Grundmann E Torhorst J et al: Haematogenous metastatic patterns in colonic carcinoma: An analysis of 1541 necropsies. J Pathol 150: 195-203, 1986.
7. Jaeck D, Bachellier P, Guiguet M et al and the Association Francaise de Chirugie: Long-term survival following resection of colorectal hepatic liver metastases. Br J Surg 84: 977-980, 1997.
8. Scheele J, Stang R, Altendorf-Hofman A and Paul M: Resection of colorectal liver metastases. World J Surg 19: 59-71, 1995.
9. Fong Y Cohen AM, Fortner JG et al: Liver resection for colorectal metastases J Clin Oncol 15: 938-946, 1997.
10. Scheele J and Altendorf-Hofman A: Resection of colorectal liver metastases. Langenbecks Arch Surg 384: 313-327, 1999.
11. Kavolius J, Fong Y and Blumgart LH: Surgical resection of metastatic liver tumors. Surg Oncol Clin N Am 5: 337-352, 1996.
12. Zadasvski KE and Lee YTM: Liver metastases from colorectal carcinoma: Incidence, resectability, and survival results. Ann Surg 60: 929-932, 1994.
13. Sullivan RD, Miller E and Skyes MP: A clinical-pharmacological evaluation of hepatic arterial infusion of 5-fluor-2-deoxyuridin and 5-fluorouracil. Cancer Res 38: 3784-3792, 1959.
14. Ackermann NB, Lien WM, Kondi ES et al: The blood supply of experimental liver metastases: I. The distribution of hepatic artery and portal vein blood to 'small' and 'large' tumours. Surgery 66: 1067-1072, 1969.
15. Heidelberger C, Chaudhuari NK, Danenberg P et al: Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature 179: 663-666, 1957.
16. Moran RG: Leucovorin enhancement of the effects of the fluoropyrimidines on thymidylate synthase Cancer 63: 1008-1012, 1998.
17. Bruckner HW and Motowani BT: Chemotherapy of advanced cancer of the colon and rectum. Semin Oncol 18: 443-461, 1991.
18. Köhne-Wömper C, Schmoll H, Harstick A and Rustum Y: Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trails. Sem Oncol 19: 105-125, 1992.
19. Chu E, Zinn S, Boarman D et al: Interaction of gamma interferon and 5-fluorouracil in the H630 human colon carcinoma cell line. Cancer Res 50: 5834-5840, 1990.
20. Findlay MPN, Raynaud F, Cunningham D et al: Measurement of Psalms 5-fluorouracil by high performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19 F spectroscopy in patients on a protracted venous infusion with and without interferon α. Ann Oncol 7: 47-53, 1996.
21. Houghton JA, Morton CL, Adkins DA, and Rahman A: Locu of interaction among 5-flurouracil, leucovorin, and α2a interferon in colon carcinoma cells Cancer Res 53: 4243-4250, 1993.
22. Sinnige HAM, Timmer-Bosscha H, Peters GF, De Vries EGE and Mulder NH: Combined modulation of leucovorin and α-2a interferon of fluoropyrimidine mediated growth inhibition. Anticancer Res 13: 1335-1340, 1993.
23. Päuser S, Reszka R, Pohlen U et al: Evaluation of efficient chemoembolization mixtures by magnetic resonance imaging therapy monitoring: an experimental study on the VX2 tumor in rabbit liver. Cancer Res 56(8): 1863-1867, 1996.
24. R) and gelatin powder (Gelfoam R). J Surg Res 92: 165-170, 2000.
25. Pohlen U, Berger G, Reszka R and Buhr HJ: Improved tumor targeting by regional carboplatin application combined with gelfoam. An experimental study on liver tumor-bearing rabbits. Chemotherapy 47: 143-149, 2001.
26. Civalleri D, Esposito M, Fulco RA et al: Liver and tumor uptake and plasma pharmacokinetic of arterial cisplatin administration with or without starch microspheres in patient with liver metastases. Cancer 68: 988-991, 1991.
27. Martin KJ, O'Connell MJ, Wieand HS et al: Intra-arterial floxuridine vs. systemic fluorouracil for hepatic metastases from colorectal cancer. Arch Surg 125: 1022-1027, 1990.
28. Kemeny N, Conti JA, Cohen A et al: Phase II study of hepatic arterial floxuridine, leucovorin and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 12: 2288-2295, 1994.
29. Kemeny N, Buyse M, Rougier P et al: A meta-analysis of hepatic arterial infusion in patients with liver metastases from colorectal cancer. Proc Am Soc Clin Oncol 15: 202-212, 1996.
30. Allen-Mersh TG, Earlam S, Fordy C et al: Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. Lancet 344: 1255-1260m, 1994.
31. Rougier P, Laplanche A, Huguier M et al: Hepatic arterial infusion of fluouridine in patients with liver metastases from colorectal carcinoma: long term results of a prospective randomized trail. J Clin Oncol 10: 1112-1118, 1992.
32. The meta-analysis group in cancer: Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. J Natl Cancer Inst 88: 252-258, 1996.
33. Harmantas A, Rotstein LE and Langer B: Regional versus systemic chemotherapy in the treatment of colorectal carcinoma metastatic to the liver: Is there a survival difference? Meta-analysis of the published literature. Cancer 78: 1639-1645, 1996.
34. Lorenz M and Müller HH for the German Cooperative Group on Liver Metastases. Randomized multicenter trail of fluorouracil plus leucovorin administered either via hepatic arterial or intravenous infusion versus fluorodeoxyuridine administered via hepatic infusion in patients with nonresectable liver metastases from colorectal carcinoma. J Clin Oncol 2: 243-254, 2000.
35. Watkins EJ, Khazei AM and Nahara KS: Surgical basis for arterial infusion chemotherapy of disseminated carcinoma of the liver. Surg Gynecol Obstet 130: 581 605, 1970.
36. Curley SA, Hohn DC and Roh MS: Hepatic artery infusion pumps: Cannulation techniques and other surgical considerations. Langenbecks Arch Chir 375: 119-124, 1990.
37. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Bethesda, MD: National Cancer Institute, 1998.
38. Miller AB, Hoogstaten B, Staquet M et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981.
39. Germer CT, Boese-Landgraf J, Albrecht D, Wagner A, Wolf KJ and Buhr HJ: The fully implantable minimally invasive hepatic artery catheter for locoregional chemotherapy of nonresectable liver metastases in defective conventional implanted therapy catheters. Chirurg 67: 458-462, 1996.
40. Collins J: Pharmacologic rationale for regional drug delivery. J Clin Oncol 2: 298-504, 1984.
41. Buyse M, Thirion P, Carlson RW, Burzykowski T, Molenberghs G and Piedbois P: Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 356: 373-378, 2000.
42. Köhne CH, Scöffski P, Wilke H et al: Effective biomodulation by leucovorin of high-dose Infusion fluorouracil given as a weekly 24-hour infusion: Results of randomized trail in patients with advanced colorectal cancer. J Clin Oncol 2: 418-426, 1998.
43. Fobbe F, Boese-Landgraf J, Chen Y et al: Intra-arterial injection of pethidine for treatment of pain in chemoembolization the liver. Rofo 161: 168-170, 1994.
44. Kemeny N, Huang Y, Cohen AM et al: Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N Eng J Med 341: 2039 2048, 1999.
45. Sigurdson ER, Kemeny N, Daly JM et al: Complications of hepatic artery infusion pump placement. Proc Am Soc Clin Oncol 10: 140. Abstract, 1991.
46. Kemeny N, Seiter K, Conti JA et al: Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update. Cancer 73: 1134-1142, 1994.
47. Kemeny N, Cohen A and Bertino JR: Continuous intrahepatic infusion of floxuridine and leucovorin through an implantable pump for treatment of hepatic metastases from colorectal carcinoma. Cancer 65: 2446-2450, 1989.
48. Schuller J, Czejaka M, Micksche M et al: Biomodulation in regional treatment in combination with interferon alpha. Reg Cancer Treat 167-170, 1992.
49. Wadler S and Schwarz EL: Chemotherapy for colorectal carcinoma. Observations regarding recent clinical trails using biochemical modulation. J Clin Oncol 13: 2676-2677, 1995.
50. WadlerS, Schwarz EL, Goldman M et al: Fluorouracil and recombinant alfa-2α-interferon: An active regimen against advanced colorectal carcinoma. J Clin Oncol 7: 1769-1775, 1989.
51. Dufour P, Husseini F, Dreyfus B et al: 5-fluorouracil versus 5-fluorouracil plus a-interferon as treatment of metastatic colorectal carcinoma. A randomized study. Ann Oncol 7: 575-579, 1996.
52. Patt YZ, Hoque A, Lozano R et al: Phase II trail of hepatic arterial infusion of fluorouracil and recombinant human interferon alfa-2b for liver metastases of colorectal cancer refractory to systemic fluorouracil and leucovorin. J Clin Oncol 4: 1432-1438, 1997.
53. Frei E and Canellos GP: Dose: Critical factor in cancer therapy. Am J Med 69: 585-59, 1980.
54. Link KH, Pillasch J, Formentini A et al: Downstaging by regional chemotherapy of primarily non-resectable isolated colorectal liver metastases. Eur J Surg Oncol 25: 381-388, 1999.
55. Staib-Sebler E, Lorenz M, Gog C et al: Continuous arterial 5-flurouracil and folinic acid chemotherapy for colorectal liver metastases. Onkologie 18: 240-244, 1995.